Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...
Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...
Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...
Hosted on MSN4d
Why NeoGenomics (NEO) Shares Are Trading Lower TodayWhat Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.The company traded as ...
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below provides a snapshot of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback